AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab before randomization
Description: Pembrolizumab 200 mg every 3 weeks before randomization
Study NCT05767372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks.
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab before randomization
Description: Pembrolizumab 200 mg every 3 weeks before randomization
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
Study NCT05703373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement
Description: Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
Study NCT05255302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab after randomization
Description: Pembrolizumab 200 mg every 3 weeks after randomization
Study NCT06217861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGM-R02b
Description: Administered as specified in the treatment arm.
Study NCT04969211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VHX-896 and iloperidone
Description: oral tablet
Study NCT04969211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone and VHX-896
Description: oral tablet
Study NCT05966246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I : Experimental (Prucalopride succinate group)
Description: Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
Study NCT05966246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm II : Control (Mosapride citrate group)
Description: Control gourp taking mosapride citrate from day 1 day 5 after surgery
Study NCT05100108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy
Description: The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
Study NCT05666570 — intervention group
Intervention type: DEVICE
Intervention: Avelle NPWT
Description: wound management therapy
Study NCT05171881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention for cerebral hypoxia
Description: For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
Study NCT04714320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-AGT-LRx
Description: Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
Study NCT04714320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Study NCT04847349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OL-1, standard dose
Description: The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
Study NCT04847349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OL-1, high dose
Description: The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
Study NCT04847349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
Study NCT04927481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study NCT06403813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
Study NCT06403813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
Study NCT04818957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)
Description: Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
Study NCT06403813 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Tooklit
Description: The toolkit will have the same screening questions, with information, but without any decision support functions.
Study NCT05800509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clips Intervention
Description: A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
Study NCT05800509 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Structured Questionnaire Only
Description: A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: oral administration
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Description: oral administration
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: oral administration
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan
Description: oral administration
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: oral administration
Study NCT06218199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: oral administration
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules, 15mg/ capsule
Description: Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone tablets, 5mg/ tablet
Description: Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study NCT06449846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: circulating tumor cell DNA detection
Description: circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
Study NCT05824455 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS109 combine with irinotecan
Description: JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
Study NCT04345302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational treatment
Description: The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist.
Study NCT04345302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
Study NCT04345302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
Study NCT05601908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Relaxation
Description: Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-904
Description: SAGE-904 oral solution.
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-904
Description: SAGE-904 oral solution.
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution.
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution.
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine intravenous (IV) infusion.
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT05049343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous (IV) infusion.
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone tablets mimic, 0mg/ tablet
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study NCT06243614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buspirone tablets mimic, 0mg/ tablet
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study NCT05399966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monarda Didyma extract
Description: Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
Study NCT05399966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
Study NCT05018494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental treatment
Description: This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
Study NCT05018494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common treatment
Description: This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
Study NCT05759208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-101
Description: Ophthalmic Solution
Study NCT05759208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05886153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vitaliti Continuous Vital Sign Monitor Model CVSM-1A
Description: Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
Study NCT04797377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous ovarian PRP injection
Description: The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
Study NCT06252844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
Study NCT06252844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control
Description: Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
Study NCT04390542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning
Study NCT05833035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583 mixed with [C-14] BI 1291583
Description: BI 1291583 mixed with \[C-14\] BI 1291583
Study NCT05289089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
Study NCT05289089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology Intervention
Description: Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
Study NCT05005871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block after C-section surgery as postoperative pain management
Description: To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
Study NCT04961138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transhepatic Arterial Chemotherapy And Embolization (TACE)
Description: Receiving TACE and lenvatinib before surgery.